Healthtech Summit 2016: SkinVision amongst Europe’s top 20 digital health companies

For its 7th edition, the Healthtech Summit will return to Lausanne on June 21 - 22, 2016 and will once again focus on showcasing the top 20 digital health companies in Europe at the IMD (Institute for Management Development) campus in Lausanne.

SkinVision is selected to showcase during the summit, to highlight the progress we have made in detecting skin cancer early through our unique app.

About the Healthtech Summit
Digital & technology innovations are starting to radically transform healthcare with Europe becoming a very vibrant playground. To deliver on their promises, Medtech and Digital Health need breakthrough ideas, talented teams, capital, and committed industry leaders.

 

 

The Healthtech Summit will offer all of this in two days of keynotes, panels, pitches and networking with a focus on high growth potential start-ups.

What we will talk about: Digital skin cancer detection
Part of SkinVision’s mission is to enable the early recognition of the world’s fastest-growing cancer issue (skin) with awareness, self-tracking & monitoring to visit a doctor in time.

Problems that we are trying to solve are numerous. With the most important ones being:
– 
People are not aware of skin cancer risk
– People try to avoid going to a doctor
– 
Skin cancer is hard to recognize for consumers, and even for doctors
– Most h
ealth systems are focused on treatment, not on prevention

We hope to see you there. For more information please see the event website here.

Share this post:
Share on facebook
Share on linkedin
Share on whatsapp

Keep your skin healthy and find skin cancer early.

Peace of mind with an accurate risk indication.

Immediate response based on machine learning technology.

Find skin cancer early. It can save your life.

More post:

Melanoma: The current situation in New Zealand

New Zealand has, together with Australia, the highest melanoma incidence in the world. The combination of skin type and UV impact from the sun put the inhibitors of New Zealand at high risk. So let’s take a closer look at the current melanoma situation in NZ.

Read More »